
Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) are currently up over 20.6% after the company released positive results from its Spectra trial.
The Spectra trial evaluates 4D-150 in patients with diabetic macular edema (DME). DME is a serious eye condition that can cause vision loss in people with diabetes.